Overexpression of fascin-1 in advanced colorectal adenocarcinoma: Tissue microarray analysis of immunostaining scores with clinicopathological parameters

Disease Markers

Volumn 23, Issue 3, 2007, Pages 153-160

  Tsai, Wen Chiuan ^a   Chao, You Chen ^a   Sheu, Lai Fa ^a   Chang, Junn Liang ^b   Nieh, Shin ^a   Jin, Jong Shiaw ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Colorectal adenoma; Colorectal cancer; Fascin 1; Immunostaining scores; Tissue microarray

Indexed keywords

FASCIN; FASCIN 1; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COLON MUCOSA; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTROINTESTINAL DYSPLASIA; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

EID: 34249905439     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/685163     Document Type: Article

References (30)

1. J.D. Potter, Colorectal cancer: molecules and population, J Natl Cancer Inst 91 (1999), 916-932.
2. S.R. Hemilton and L.A. Aaltonen, WHO classification of tumors: tumors of the digestive system, Lyon: IRAC press, 2000, 105-119.
3. S. Sasaki, T. Masaki, N. Umetani et al., Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observation, Jpn J Clin Oncol 28 (1998), 202-206.
4. B. Cagir, M.W. Nagy, A. Topham et al., Adenosquamous carcinoma of the colon, rectum, and anus: epidemiology, distribution, and survival characteristics, Dis Colon Rectum 42 (1999), 258-263.
5. J.P. Cerottini, S. Caplin, S. Pampallona et al., Prognostic factors in colorectal cancer, Oncol Rep 6 (1999), 409-414.
6. M. Pignatelli and W.F. Bodmer, Integrin cell adhesion molecules and colorectal cancer, J Pathol 162 (1990), 95-97.
7. M. Pignatelli, D. Liu, M.M. Nasim et al., Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells, Br J Cancer 66 (1992), 629-634.
8. A.U. Jawhari, A. Buda, M. Jenkins et al., Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro, Am J Pathol 162 (2003), 69-80.
9. J.C. Adams, Roles of fascin in cell adhesion and motility, Curr Opin Cell Biol 16 (2004), 590-596.
10. F.M. Duh, F. Latif, Y. Weng et al., cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein, DNA Cell Biol 13 (1994), 821-827.
11. B.E. Tubb, S. Bardien-Kruger, C.D. Kashork et al., Characterization of human retinal fascin gene (FSCN2) at 17q25: close physical linkage of fascin and cytoplasmic actin genes, Genomics 65 (2000), 146-156.
12. B. Tubb, D.J. Mulholland, W. Vogl et al., Testis fascin (FSCN3): a novel paralog of the actin-bundling protein fascin expressed specifically in the elongate spermatid head, Exp Cell Res 275 (2002), 92-109.
13. G. Mosialos, M. Birkenbach, S. Ayehunie et al., Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein, Am J Pathol 148 (1996), 593-600.
14. A. Grothey, R. Hashizume, A.A. Sahin et al., Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer, Br J Cancer 83 (2000), 870-873.
15. A.A. Roma and R.A. Prayson, Fascin expression in 90 patients with glioblastoma multiforme, Ann Diagn Pathol 9 (2005), 307-311.
16. J.J. Xie, L.Y. Xu, H.H. Zhang et al., Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells, Biochem Biophys Res Commun 337 (2005), 355-362.
17. Y. Hashimoto, Y. Shimada, J. Kawamura et al., The prognostic relevance of fascin expression in human gastric carcinoma, Oncology 67 (2004), 262-270.
18. G. Pelosi, U. Pastorino, F. Pasini et al., Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br J Cancer 88 (2003), 537-547.
19. G.X. Tong, H. Yee, L. Chiriboga et al., Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder, Hum Pathol 36 (2005), 741-746.
20. G. Fan, P. Kotylo, R.S. Neiman et al., Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease, Am J Clin Pathol 119 (2003), 199-204.
21. J. Jacquemier, C. Ginestier, F. Bertucci, J. Geneix and D. Birnbaum, Tissue microarrays: a powerful tool in transfer and quality control in oncology, Bull Cancer 90 (2003), 31-38.
22. W.C. Tsai, L.F. Sheu, S. Nieh et al., Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters, World J Urol (2006), Article in press.
23. J.S. Jin, C.P. Yu, G.H. Sun et al., Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness, Histol Histopathol 21 (2006), 1287-1293.
24. Y. Hashimoto, M. Skacel and J.C. Adams, Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37 (2005), 1787-1804.
25. A. Buda and M. Pignatelli, Cytoskeletal network in colon cancer: from genes to clinical application, Int J Biochem Cell Biol 36 (2004), 759-765.
26. J.S. Lam, A.S. Belldegrum and R.A. Figlin, Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy, Clin Cancer Res 10 (2004), 6304s-6309s.
27. N. Kureishy, V. Sapountzi, S. Prag et al., Fascins, and their roles in cell structure and function, Bioessays 24 (2002), 350-361.
28. J.C. Adams, Fascin protrusions in cell interactions, Trends Cardiovasc Med 14 (2004), 221-226.
29. Y. Hashimoto, T. Ito, H. Inoue et al., Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma, Clin Cancer Res 11 (2005), 2597-2605.
30. B.J. Yoder, E. Tso, M. Skacel et al., The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course, Clin Cancer Res 11 (2005), 186-192.